Project Grant R01CA296410
Award Date
1/10/25
Completion Date
12/31/29
Dollars Obligated
$590K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $659,090 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Johns Hopkins University to develop a mutant KRAS-targeted vaccine for the interception of pancreatic cancer progression. The 5-year grant aims to evaluate the safety and immunogenicity of the vaccine in individuals with genetic predisposition to pancreatic cancer as well as those with high-risk premalignant lesions. The researchers will study the vaccine's...
This federal Project Grant award of $336,257.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV MMR-P pancreatic ductal adenocarcinoma. The 3-year award, which runs from September 1, 2024 to August 31, 2027, is granted to The Johns Hopkins University, a private non-profit research institution...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a novel targeted approach for treating K-RAS(G12C) mutation-driven cancers. The $269,280 award, active from February 2025 to January 2027, supports research at Cold Spring Harbor Laboratory to investigate covalent labeling and targeted degradation of the K-RAS(G12C) oncogenic driver. The project involves synthesizing a library of hybrid ligands to evaluate their selectivity and...
This $546,625 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop a new immunochemotherapy approach for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered under this 5-year award include: Developing and characterizing a novel nanoparticle carrier system that can co-deliver small interfering RNA (siRNA) targeting the IRHOM1 protein and a chemotherapeutic agent...
This Project Grant award of $356,850 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports a research effort led by The Medical College of Wisconsin, Inc. to characterize KRAS and other RAS gene mutations that may confer sensitivity to EGFR inhibitor drugs in colorectal cancer. The overarching goal is to identify additional RAS mutants that could benefit from EGFR-targeted therapies, which are currently limited due to the assumption that RAS mutations...
This $835,531 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund a research project at The Johns Hopkins University to develop a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV mismatch repair-proficient (MMR-P) pancreatic ductal adenocarcinoma. The project aims to transform healthcare for military service members and the broader...
The National Cancer Institute (NCI) awarded a $205,700 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer. The research aims to explore a novel combination approach of DNA repair inhibition and targeted therapy to prevent the emergence of resistance. Through analysis of clinical samples, cell lines, and...
This $640,583 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance the efficacy of immunotherapy against metastatic colorectal cancer (mCRC). The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells, which can boost the metabolic fitness and anti-tumor activity of these immune cells within the mCRC tumor microenvironment. The research will investigate the specific mechanisms by which PPARD activation...
This $698,456.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports the "Development of a Universal mRNA Vaccine Targeting APC Mutations for Colorectal Cancer Prevention" at the Sloan-Kettering Institute for Cancer Research in New York, NY. The three-year award, running from November 1, 2024 to October 31, 2027, will fund innovative research to develop a novel mRNA-based vaccine targeting...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University aims to develop an innovative approach to inactivate mutant KRAS in metastatic colon cancer. The $497,002 award will fund research to load a CRISPR/Cas9-based epigenetic repressor complex into exosomes, along with KRAS-targeting siRNAs and chemotherapeutic agents, to specifically silence mutant KRAS and inhibit metastasis. The project involves sub-awards to the...